NASDAQ:RTTR Ritter Pharmaceuticals (RTTR) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free RTTR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.30▼$0.3250-Day Range$0.45▼$4.0952-Week Range$0.15▼$1.27Volume17,610 shsAverage Volume14.23 million shsMarket Capitalization$13.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Ritter Pharmaceuticals alerts: Email Address Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About Ritter Pharmaceuticals Stock (NASDAQ:RTTR)Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.Read More Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). RTTR Stock News HeadlinesJanuary 24, 2024 | health.usnews.comDr. John D. RitterSeptember 15, 2023 | health.usnews.comKristen RitterApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.July 8, 2023 | health.usnews.comDr. Harold K. RitterJuly 1, 2023 | bizjournals.comDenver Business Journal welcomes new tech reporterApril 10, 2023 | usatoday.comJason Ritter and Drew Barrymore's raw conversation on her show may matter more than you thinkMarch 29, 2023 | thestreet.comRitter Pharmaceuticals Changing the Game With Lactose Intolerance TreatmentMarch 18, 2023 | finance.yahoo.comGlobal Microbiome Market Report 2023: Major Players Include MicroBiome Therapeutics, Seres Therapeutics, Enterome Bioscience and Second GenomeApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.January 19, 2023 | yahoo.comMelanie Lynskey's husband Jason Ritter will join her in Yellowjackets this seasonNovember 16, 2022 | finance.yahoo.comMicrobiome Clinical Trial Pipeline Space Brims with Novel Emerging Therapies with 130+ Key Players Working in the Domain | DelveInsightSee More Headlines Receive RTTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ritter Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2020Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:RTTR CUSIPN/A CIK1460702 Webwww.ritterpharmaceuticals.com Phone310-203-1000FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,130,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-162.05% Debt Debt-to-Equity RatioN/A Current Ratio3.67 Quick Ratio3.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book2.97Miscellaneous Outstanding Shares46,153,000Free FloatN/AMarket Cap$13.71 million OptionableNot Optionable Beta-0.43 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Ira Eliot Ritter (Age 70)Co-Founder, Exec. Chairman & Chief Strategic Officer Mr. Andrew J. Ritter (Age 36)Co-Founder, CEO, Pres, Corp. Sec. & Director Mr. Michael D. Step (Age 59)Consultant & Director Mr. John W. Beck CPA (Age 59)CPA, Chief Financial Officer Ms. Ellen F. Mochizuki (Age 52)Consultant Key CompetitorsEdesa BiotechNASDAQ:EDSAABVC BioPharmaNASDAQ:ABVCNeuroBo PharmaceuticalsNASDAQ:NRBOTraws PharmaNASDAQ:TRAWAytu BioPharmaNASDAQ:AYTUView All Competitors RTTR Stock Analysis - Frequently Asked Questions How were Ritter Pharmaceuticals' earnings last quarter? Ritter Pharmaceuticals Inc (NASDAQ:RTTR) posted its quarterly earnings data on Friday, May, 1st. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01. When did Ritter Pharmaceuticals' stock split? Shares of Ritter Pharmaceuticals reverse split before market open on Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 22nd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Ritter Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ritter Pharmaceuticals investors own include Endologix (ELGX), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Charles Schwab (SCHW), Genocea Biosciences (GNCA), Hudson Technologies (HDSN), Vicor (VICR), Zoetis (ZTS) and When did Ritter Pharmaceuticals IPO? Ritter Pharmaceuticals (RTTR) raised $20 million in an initial public offering on Wednesday, June 24th 2015. The company issued 4,000,000 shares at $5.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO and Barrington Research was co-manager. This page (NASDAQ:RTTR) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ritter Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
